Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

11.70 +0.12 (+1.04%)
Streaming Delayed Price Updated: 10:13 AM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fulcrum Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Advances TAEUS® Liver Imaging, Strengthens Capital Efficiency; WVE, TWG, BDRX, FULC Also Active
Via AB Newswire
News headline image
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For October 29, 2025 ↗
 
Via Benzinga
News headline image
What's going on in today's session ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
News headline image
Wondering what's happening in today's pre-market session? ↗
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
Fulcrum Stock Nears March 2024 Highs: Early Stage Sickle-Cell Data Sparks Target Price Hikes ↗
On Saturday, the company reported promising early outcomes from its Phase 1b PIONEER trial for sickle cell disease (SCD). 
Via Stocktwits
News headline image
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Gorilla Technology Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their outstanding shares is at $5.6 million. 
Via Benzinga
News headline image
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics to Present at Upcoming Investor Meetings
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Small-Cap Stocks: An Undervalued Opportunity in a Cautious Market?
In a financial landscape increasingly dominated by the towering valuations of large-cap technology giants, a quieter, yet potentially profound, narrative is unfolding within the small-cap segment of... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.